Results 101 to 110 of about 23,909 (233)

Clinical and genetic landscape of epilepsies with absence seizures and single‐gene etiology

Epilepsia, EarlyView.
Abstract Objective To characterize the clinical, electroencephalographic, and genetic features of epilepsies featuring absence seizures within monogenic etiology, highlighting the diagnostic, treatment and prognostic implications. Methods We conducted a retrospective, multicenter study including patients with monogenic epilepsies and ...
Simona Balestrini, Ilaria Galli, Maria Luisa Ricci, Elena Parrini, Davide Mei, Mario Mastrangelo, Francesco Pisani, Corinna Filippi, Lucio Giordano, Elisabetta Cesaroni, Carla Marini, Emanuele Cerulli Irelli, Carlo di Bonaventura, Marica Rubino, Antonietta Coppola, Jacopo Proietti, Tommaso Lo Barco, Francesca Darra, Laura Licchetta, Francesca Bisulli, Marco Perulli, Domenica Battaglia, Angela De Dominicis, Marina Trivisano, Nicola Specchio, Roberta Solazzi, Davide Caputo, Laura Canafoglia, LICE Collaborative group, Carmen Barba, Emanuele Bartolini, Pia Bernardo, Maria Paola Canevini, Gaetano Cantalupo, Susanna Casellato, Mara Cavallin, Ilaria Contaldo, Alessandro Ferretti, Maria Luigia Gambardella, Tiziana Granata, Giuliana Lentini, Anna Luchetti, Federico Melani, Pasquale Parisi, Simona Pellacani, Laura Pietrangelo, Tiziana Pisano, Ilaria Onida, Emilia Ricci, Aglaia Vignoli, Renzo Guerrini   +50 more
wiley   +1 more source

Correlation Between Cannabidiol-Induced Reduction of Infarct Volume and Inflammatory Factors Expression in Ischemic Stroke Model

Basic and Clinical Neuroscience, 2017
Introduction: Recent studies demonstrated that cannabidiol had neuroprotective property. Thereis some evidence about effective role of cannabidiol in reducing ischemic damages. It has been reported that infarct size is influenced by various factors after
Sepideh Khaksar, Mohammad Reza Bigdeli
doaj  

Subthreshold Cannabidiol Potentiates Levetiracetam in the Kainic Acid Model of Temporal Lobe Epilepsy: A Pilot Study

Pharmaceuticals
Refractoriness to antiseizure medications is still a major concern in the pharmacotherapy of epilepsy. For this reason, we decided to evaluate the combination of levetiracetam and cannabidiol, administered at a subthreshold dose, to limit the possible ...
Chiara Lucchi, Mattia Marcucci, Kawther Ameen Muhammed Saeed Aledresi, Anna-Maria Costa, Giuseppe Cannazza, Giuseppe Biagini   +5 more
doaj   +1 more source

Bexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial (PACIFIC)

Epilepsia, EarlyView.
Abstract Objective This randomized, double‐blind, phase 1b/2a clinical trial was designed to evaluate the safety, tolerability, and efficacy of oral bexicaserin versus placebo for the treatment of seizures in adolescents and adults with developmental and epileptic encephalopathies (DEEs).
Dennis J. Dlugos, Ingrid E. Scheffer, Jacqueline A. French, David G. Vossler, Chad Orevillo, Shikha Polega, Randall Kaye, and the LP352‐201 Study Investigators, Kore Liow, Ena Zhu, Jennifer Waldron, Hayley Groubert, Alexis Anderson, Pavel Klein, Salman Hashmi, Shicong Ye, Anita Farhi, David Vossler, Dione M. Froman, Shannon L. Hoffman‐Huffaker, Ki Hyeong Lee, AnnaLyn Dallas, Amir Arain, Laura Beeler, Michael Macken, Irena Bellinski, Elizabeth Cunningham, James Renfroe, Shezsay Colbert, Robert Hogan, Patty Schaefer, Susan Shaw, Sheetal Desai, Ahmed Sadek, Haile Robertson, Kamil Detyniecki, Anabela Cieslicki, Ruben Kuzniecky, Sarah Goodman, Selim Benbadis, Marina Azevedo, Sami Aboumatar, Julie Biel, Nilika Singhal, Emerald Wan, Evan Fertig, Hannah Hart, Debopam Samanta, Sarah Hankins, Steven Wolf, Patricia Pena, Robert Nahouraii, M. J. Mari, David Burdette, Stephanie Mueller, Karen Keough, Victoria Henderson, Talitha Durgin, Terence O’Brien, Rafael Smith, Jack Germaine, Kate Riney, Lori Anthony, David Reutens, Kimberley Irwin, Michael Fahey, Melissa Batt, Stephanie Kaladis, Kasthoori Jeyachanthiran, Ingrid Scheffer, Rebecca Wharrie, Greesha Zacharia, Brittany Walsh, Heather Robinson, Sharon Ganter   +74 more
wiley   +1 more source

Lennox–Gastaut syndrome unveiled: Advancing diagnosis, therapies, and advocacy‐insights from the Genoa International Workshop

Epilepsia, EarlyView.
Abstract Lennox–Gastaut syndrome (LGS) is one of the most severe, yet one of the most discussed, childhood‐onset developmental and epileptic encephalopathies (DEEs). Dissent among epileptologists on the definition and minimum set of electroclinical features derives from the high etiological heterogeneity within the syndrome, which could make its ...
Antonella Riva, Gianluca D'Onofrio, Elisabetta Amadori, Alexis Arzimanoglou, Stéphane Auvin, Irene Bagnasco, Paola Barabino, Valentina Biagioli, Isabella Brambilla, Giuliana Cangemi, Antonietta Coppola, Antonella De Lillo, Carlo Di Bonaventura, Giancarlo Di Gennaro, Edoardo Ferlazzo, Antonio Gil‐Nagel, Giuseppe Gobbi, Simona Lattanzi, Gerhard Kluger, Günter Krämer, Maria Margherita Mancardi, Carlo Minetti, Lino Nobili, Elisa Paravati, Milka Pringsheim, Erika Rebessi, Antonino Romeo, Angelo Russo, Emilio Russo, Katia Santoro, Susanne Schubert‐Bast, Laura Siri, Jo Sourbron, Maria Stella Vari, Alberto Verrotti, Flavio Villani, Maurizio Viri, Celina von Stülpnagel, Nelia Zamponi, Federico Zara, Pasquale Striano   +40 more
wiley   +1 more source

Epilepsy in dentatorubral–pallidoluysian atrophy: A systematic review and meta‐analysis

Epilepsia, EarlyView.
Summary of key clinical and electrophysiological characteristics of DRPLA‐related epilepsy from a systematic review and meta‐analysis of 1,191 patients. DRPLA patients with epilepsy showed earlier disease onset, longer CAG repeat expansion, and a tendency toward paternal inheritance. EEG findings frequently included photoparoxysmal responses.
Toru Horinouchi, Haruka Ishibashi, Yukako Nakagami, Yoko Kobayashi Takahashi, Takato Akiba, Masaharu Miyauchi, Naohiro Yamamoto, Ryoichi Inoue, Satoshi Kodama, Takafumi Kubota, Naoto Kuroda   +10 more
wiley   +1 more source

Quantitative Analyses of Synergistic Responses between Cannabidiol and DNA-Damaging Agents on the Proliferation and Viability of Glioblastoma and Neural Progenitor Cells in Culture [PDF]

, 2016
Liting Deng, Lindsay Ng, Tatsuya Ozawa, Nephi Stella   +3 more
openalex   +1 more source

Epilepsy treatment over time: The chess game analogy for choosing, adjusting, and adding antiseizure medications

Epilepsia, EarlyView.
Abstract Recurrent seizures have such a negative impact upon the lives of persons with epilepsy that their prevention is a constant preoccupation of neurologists. Despite the large number of antiseizure medications (ASMs) currently available and of publications on their putative efficacy, adverse effects, and order of preference to start treatment ...
André Palmini, André Gus, Lecio Figueira Pinto   +2 more
wiley   +1 more source

Pediatric Investigation Plans for seizure and epilepsy treatments: An analysis since the implementation of the European Pediatric Regulation in 2006

Epilepsia, EarlyView.
Abstract Objective A Pediatric Investigation Plan (PIP) implemented under the European Pediatric Regulation (EC No. 1901/2006) aims to ensure early and systematic evaluation of medicines for children. We analyze PIPs for antiseizure medications (ASMs) submitted to the European Medicines Agency (EMA) since 2006, characterizing their content, focusing on
Valeria Agostini, Stéphane Auvin
wiley   +1 more source

Clinical trajectories and medication response in TBC1D24‐related epilepsies

Epilepsia, EarlyView.
Abstract Objective Biallelic variants in TBC1D24 represent a rare cause of epilepsy and neurodevelopmental disorders, including severe developmental and epileptic encephalopathies. Here, we present the first attempt to delineate the longitudinal disease histories and effectiveness of antiseizure medications (ASMs) in TBC1D24‐related disorders.
Ealing Mondragon, Jan H. Magielski, Bintou Bane, JoeyLynn Nolan, Sarah M. Ruggiero, Dallas Armstrong, Susan Arnold, Deepa Sirsi, Ingo Helbig, Jillian L. McKee   +9 more
wiley   +1 more source